BRPI0309730B8 - antibody molecule having specificity for human cd22, DNA sequence, expression or cloning vector, host cell, use of the antibody molecule or DNA sequence, diagnostic or therapeutic composition, process for producing an antibody molecule, process for the preparation of a diagnostic or therapeutic composition - Google Patents
antibody molecule having specificity for human cd22, DNA sequence, expression or cloning vector, host cell, use of the antibody molecule or DNA sequence, diagnostic or therapeutic composition, process for producing an antibody molecule, process for the preparation of a diagnostic or therapeutic compositionInfo
- Publication number
- BRPI0309730B8 BRPI0309730B8 BRPI0309730A BRPI0309730A BRPI0309730B8 BR PI0309730 B8 BRPI0309730 B8 BR PI0309730B8 BR PI0309730 A BRPI0309730 A BR PI0309730A BR PI0309730 A BRPI0309730 A BR PI0309730A BR PI0309730 B8 BRPI0309730 B8 BR PI0309730B8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody molecule
- diagnostic
- dna sequence
- therapeutic composition
- antibody
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
molécula de anticorpo, variante desta, seqüência de dna, vetor de expressão ou clonagem, célula hospedeira, uso da molécula de anticorpo ou da seqüência de dna, composição diagnóstica ou terapêutica, processo para a produção de uma molécula de anticorpo, processo para a preparação de uma composição diagnóstica ou terapêutica, e, polipeptídeo. são descritas moléculas de anticorpo contendo pelo menos uma cdr derivada de um anticorpo monoclonal de camundongo possuindo especificidade para cd22 humana. também é descrito um anticorpo enxertado com cdr no qual pelo menos uma das cdrs é uma cdr modificada. são adicionalmente descritas seqüências de dna codificadoras de cadeias de moléculas de anticorpo, vetores, células hospedeiras transformadas e usos das moléculas de anticorpo no tratamento de doenças mediadas por células expressando cd22.antibody molecule, variant thereof, DNA sequence, expression or cloning vector, host cell, use of the antibody molecule or DNA sequence, diagnostic or therapeutic composition, process for the production of an antibody molecule, process for the preparation of a diagnostic or therapeutic composition, and, polypeptide. antibody molecules containing at least one cdr derived from a mouse monoclonal antibody having specificity for human cd22 are described. also described is a cdr-grafted antibody in which at least one of the cdrs is a modified cdr. further described are DNA sequences encoding antibody molecule chains, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing cd22.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0210121.0A GB0210121D0 (en) | 2002-05-02 | 2002-05-02 | Biological products |
| GB0210121.0 | 2002-05-02 | ||
| GB0393320 | 2003-05-02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0309730A2 BRPI0309730A2 (en) | 2019-03-12 |
| BRPI0309730B1 BRPI0309730B1 (en) | 2021-05-04 |
| BRPI0309730B8 true BRPI0309730B8 (en) | 2021-05-25 |
Family
ID=67225936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0309730A BRPI0309730B8 (en) | 2002-05-02 | 2003-05-02 | antibody molecule having specificity for human cd22, DNA sequence, expression or cloning vector, host cell, use of the antibody molecule or DNA sequence, diagnostic or therapeutic composition, process for producing an antibody molecule, process for the preparation of a diagnostic or therapeutic composition |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BRPI0309730B8 (en) |
-
2003
- 2003-05-02 BR BRPI0309730A patent/BRPI0309730B8/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0309730B1 (en) | 2021-05-04 |
| BRPI0309730A2 (en) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0106682B8 (en) | antibody molecule, compound, DNA sequence, cloning or expression vector, host cell, process for producing the antibody molecule, therapeutic or diagnostic composition, use of the antibody molecule and use of the compound | |
| BR0212756A (en) | Antibody molecule having specificity for human kdr, antibody molecule variant, compound, DNA sequence, vector, host cell, process for producing the antibody molecule, therapeutic or diagnostic composition, and use of the antibody molecule | |
| UA92580C2 (en) | Antibodies specific for human cd22 and their therapeutic and diagnostic uses | |
| BR112019012040A2 (en) | isolated antibody or fragment thereof, composition, isolated cell, and methods for treating cancer, detecting cd73 expression in a sample and identifying a cancer patient suitable for treatment with an anti-cd73 therapy. | |
| BRPI0407233A (en) | Neutralizing antibody, antibody molecule, cdr-grafted antibody, isolated dna sequence, cloning or expression vector, host cell, process for producing the antibody molecule, and, pharmaceutical composition | |
| BR112019023992A2 (en) | ANTIBODY OR FRAGMENT FOR BINDING THE ANTIGEN OF THE SAME, ITS PRODUCTION METHOD, ITS USES, AS WELL AS A NUCLEIC ACID MOLECULE, CLONING OR EXPRESSION VECTOR, HOST CELL, HYBRIDOMA, PHARMACEUTICAL AND IMMUNE PHARMACEUTICAL COMPOSITION | |
| AR046833A1 (en) | ANTI-INTERLEUQUINA ANTIBODIES-10 | |
| BR9007197A (en) | HEAVY CHAIN, LIGHT CHAIN AND ANTIBODY MOLECULE, DNA SEQUENCE, CLONING VECTOR, HOST CELL, PROCESSES TO PRODUCE AN ANTIBODY SEQUENCE AND AN ANTIBODY PRODUCT, THERAPEUTIC COMPOSITION AND THERAPY OR DIAGNOSE PROCESS | |
| EA200801509A1 (en) | HUMAN MONOCLONAL ANTIBODIES TO PROTEINTHYROSINKINASE 7 (PTK7) AND METHODS OF APPLICATION OF ANTIBODIES AGAINST PTK7 | |
| CY1110848T1 (en) | NOGO HUMAN ANTI-ANTIQUE AND THE PHARMACEUTICAL OF THE USE | |
| CN118176215A (en) | Novel anti-L1 CAM antibodies | |
| BRPI0309730B8 (en) | antibody molecule having specificity for human cd22, DNA sequence, expression or cloning vector, host cell, use of the antibody molecule or DNA sequence, diagnostic or therapeutic composition, process for producing an antibody molecule, process for the preparation of a diagnostic or therapeutic composition | |
| BRPI0410655A (en) | pharmaceutical composition, method of treating or preventing a rabies virus infection in an individual in need of this treatment, recombinant rhabdovirus expression vector, mammalian host cell, method of producing a recombinant human rabies virus neutralizing antibody in a mammal, and, use of a combination | |
| ES2150937T3 (en) | AUTOTAXIN: STIMULATING PROTEIN OF USEFUL MOTILITY IN DIAGNOSIS AND CANCER THERAPY. | |
| Lampman et al. | Amino acid sequence of a platelet-binding human anti-DNA monoclonal autoantibody | |
| CN114516917B (en) | Humanized anti-TrkA antibody and application thereof | |
| JP2024540383A (en) | Novel anti-L1CAM antibody | |
| TW202426499A (en) | PH-dependent anti-CTLA4 antibody or antigen-binding fragment | |
| BR112023018987A2 (en) | CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN-3 AND CANCER TREATMENT METHODS | |
| WO2024191972A3 (en) | Anti-lipocalin-2 antibodies and uses thereof | |
| CN118206657A (en) | Antibody of galectin-3 and application thereof | |
| ATE332311T1 (en) | POLYPEPTIDE AND NUCLEIC ACID CODING THEREFOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: ANULADA PUBLICACAO 6.7 DA RPI 1878 DE 02/01/2007 POIS A MESMA FOI INDEVIDA. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: UCB S.A. (BE) |
|
| B25A | Requested transfer of rights approved |
Owner name: UCB PHARMA S.A. (BE) |
|
| B65X | Notification of requirement for priority examination of patent application | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/05/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/05/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 02/05/2023 |